Dr Reddy's Laboratories Ltd on Wednesday said it has signed a licensing pact with US-based Ingenus Pharmaceuticals, LLC, to commercialise Cyclophosphamide injection used in treatment of cancer. The company's wholly-owned subsidiary Dr Reddy's Laboratories Inc and Ingenus Pharmaceuticals, LLC have entered into license agreement, Dr Reddy's Laboratories Ltd (DRL) said in a regulatory filing.

Reddy博士实验室有限公司周三表示，已与美国Ingenus Pharmaceuticals，LLC签署许可协议，将用于治疗癌症的环磷酰胺注射液商业化。该公司的全资子公司Reddy's Laboratories Inc和Ingenus Pharmaceuticals，LLC已签署许可协议，Reddy's Laboratories Ltd（DRL）博士在监管文件中表示。

Modi 3.0 LiveModi 3.0 is here! Familiar faces, fresh additions, and the big portfolio puzzleModi-fying growth: India plans policy twist for jobs & investmentNo place for losers: Modi sends a clear message with Cabinet 3.0 Subsequently, Dr Reddy's Laboratories Inc (Dr Reddy's USA) has licensed from Ingenus, the exclusive rights to commercialise Cyclophosphamide injection of strengths 500 mg/2.5mL; 1g/5mL; 2g/10mL in the US, it added.

Modi 3.0 LiveModi 3.0在这里！熟悉的面孔，新加入的人，以及困惑增长的大投资组合：印度计划扭转就业和投资政策没有失败者的位置：Modi用Cabinet 3.0发出了一个明确的信息随后，Reddy博士的实验室公司（Reddy博士的美国）从Ingenus获得了商业化500毫克/2.5毫升环磷酰胺注射液的专有权；1g/5mL；它补充说，在美国为2g/10mL。

Under the in-licensing pact, Dr Reddy's USA will commercialise the Cyclophosphamide injection for the US market and will pay Ingenus 50 per cent of the calculated profit share and no other consideration is payable, the filing said. The sales of the said Ingenus product as per the IQVIA for the past 12 months ended March 2024 was USD 51.8 million, it added.

根据in许可协议，Reddy博士的美国公司将在美国市场将环磷酰胺注射液商业化，并将向Ingenus支付计算利润份额的50%，无需支付其他对价，备案文件称。据IQVIA统计，截至2024年3月的过去12个月，上述Ingenus产品的销售额为5180万美元。

The parties will enter into a commercial supply agreement pursuant to which Ingenus will supply the product to Dr Reddy's USA, the company said.(You can now subscribe to our Economic Times WhatsApp channel)(You can now subscribe to our Economic Times WhatsApp channel).

该公司表示，双方将签订商业供应协议，根据该协议，Ingenus将向Reddy博士的美国供应该产品。（您现在可以订阅我们的经济时报WhatsApp频道）（您现在可以订阅我们的经济时报WhatsApp频道）。